Recently, Yichang Renfu Pharmaceutical received the Drug Registration Certificate for Remimazolam Tosylate Injection approved and issued by the National Medical Products Administration, approving the addition of a new indication for this product: "Used as a sedative during mechanical ventilation in intensive care."

Remimazolam Tosylate Injection is a new type of benzodiazepine jointly developed by Yichang Renfu and the German company PAION. It is an ultra-short-acting GABAa receptor agonist. This product is a Class 1 new drug approved for marketing by Yichang Renfu in July 2020, with previously approved indications including "sedation and anesthesia during surgeries/procedures without tracheal intubation" and "induction and maintenance of general anesthesia."

As a leading domestic company in the anesthesia subfield, Yichang Renfu is committed to meeting clinical needs by developing anesthetic and sedative drugs that act faster, have better efficacy, and fewer side effects. Remimazolam Tosylate Injection not only breaks the nearly 30-year stagnation in innovative sedative drug launches domestically and internationally but is also the first Class 1 chemical drug approved in Hubei Province. The approval of this new indication will provide clinicians with more diverse medication options, promote the development of patient-centered intensive care treatment concepts, and further enhance the company's competitiveness in the domestic anesthesia subfield market.